A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT05584670. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy or in Combination With Other Anticancer Therapies in Adults With Advanced Solid Tumors
Study identification
- NCT ID
- NCT05584670
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Sanofi
- Industry
- Enrollment
- 542 participants
Conditions and interventions
Conditions
Interventions
- ADG126 Drug
- Bevacizumab Drug
- Cetuximab Drug
- Ipilimumab Drug
- Nivolumab Drug
- SAR445877 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 28, 2022
- Primary completion
- Jan 18, 2027
- Completion
- Jun 27, 2028
- Last update posted
- Jan 19, 2026
2022 – 2028
United States locations
- U.S. sites
- 9
- U.S. states
- 9
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Christiana Care Health System- Site Number : 8400011 | Newark | Delaware | 19713-2072 | Recruiting |
| University of Iowa- Site Number : 8400014 | Iowa City | Iowa | 52242-1009 | Recruiting |
| University of Kansas Cancer Center Clinical Research Center (Fairway) Site Number : 8400008 | Fairway | Kansas | 66205-2528 | Recruiting |
| Barbara Ann Karmanos Cancer Institute - Detroit- Site Number : 8400006 | Detroit | Michigan | 48201 | Recruiting |
| John Theurer Cancer Center Site Number : 8400001 | Hackensack | New Jersey | 07601 | Recruiting |
| NYU Langone Medical Center-New York- 550 1st Ave - BRANY - PPDS- Site Number : 8400013 | New York | New York | 10016-6402 | Recruiting |
| Rhode Island Hospital Site Number : 8400004 | Providence | Rhode Island | 02903 | Recruiting |
| University of Texas MD Anderson Cancer Center Site Number : 8400005 | Houston | Texas | 77030-4000 | Recruiting |
| Fred Hutchinson Cancer Center - 825 Eastlake Ave E- Site Number : 8400010 | Seattle | Washington | 98109-4405 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05584670, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 19, 2026 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05584670 live on ClinicalTrials.gov.